Introduction
============

Renal cell carcinoma (RCC), accounting for approximately 3% of human malignant tumors, is a common type of adult kidney tumor ([@b1-ol-0-0-9871]). Globally, over 260,000 patients are diagnosed with kidney tumor annually and over 116,000 patients succumb to the disease ([@b2-ol-0-0-9871]). The 5-year survival rate for RCC patients in advanced stages remains poor due to metastasis or recurrence ([@b3-ol-0-0-9871]). Generally, the standard therapies for RCC involve nephron sparing surgery and radical nephrectomy ([@b4-ol-0-0-9871],[@b5-ol-0-0-9871]). However, these types of therapies are not expected to have curative effects as they only slightly extend progression-free survival ([@b6-ol-0-0-9871]). Therefore, further understanding of the molecular mechanisms underlying RCC metastasis and progression is of great importance to identify novel prognostic and diagnostic biomarkers for RCC.

miRNAs are a class of conserved non-coding RNAs, serving important roles in regulating gene expression levels via directly targeting the mRNA 3′-UTR to induce translation inhibition or mRNA degradation ([@b7-ol-0-0-9871],[@b8-ol-0-0-9871]). miRNAs have been confirmed to be involved in different kinds of cellular processes, such as apoptosis, metabolism, and differentiation ([@b9-ol-0-0-9871]--[@b11-ol-0-0-9871]). The study of miRNAs has provided a new direction in our understanding of the tumorigenic mechanism of RCC. Additionally, aberrant expression levels of various miRNAs have been observed in RCC. For instance, Song *et al* reported that miR-384 could repress RCC cell invasion and growth via regulating astrocyte elevated gene 1 ([@b12-ol-0-0-9871]). Wang *et al* reported that migration and invasion abilities of RCC were suppressed by miR-182 through the regulation of *IGF1R* ([@b13-ol-0-0-9871]). Hu *et al* revealed that miR-138 repressed RCC cell invasion and proliferation by mediating *SOX9* ([@b14-ol-0-0-9871]). Thus, miRNAs may be underlying diagnostic markers for RCC.

Epithelial-mesenchymal transition (EMT) is a pathological and physiological process where epithelial cells lose their polarity and cell-cell adhesion signature, acquiring the mesenchymal characteristics ([@b15-ol-0-0-9871],[@b16-ol-0-0-9871]). During this progress, the expression levels of epithelial markers, such as E-cadherin, increase, while the expression levels of mesenchymal markers, such as vimentin, decrease ([@b17-ol-0-0-9871]). EMT plays a critical role in many aspects of tumor behavior, including metastasis ([@b18-ol-0-0-9871]). Thus, further investigation is essential to better understand the mechanisms underlying EMT progression in RCC.

*ATAD2* (ATPase family AAA domain-containing protein 2), also known as AAA^+^ nuclear coregulator cancer associated (ANCCA), is a member of the AAA^+^ ATPase family ([@b19-ol-0-0-9871]). *ATAD2* contains both an ATPase domain and a bromodomain. Additionally, *ATAD2* maps to chromosome 8q24, which is the most commonly amplified region in multiple tumors ([@b20-ol-0-0-9871],[@b21-ol-0-0-9871]). The special structures of *ATAD2* indicated that it was implicated in the regulation of genome, including cell differentiation, apoptosis, division and proliferation ([@b22-ol-0-0-9871],[@b23-ol-0-0-9871]). Recently, dysregulation of *ATAD2* has been found in various tumors, playing significant roles in tumor progression. For example, *ATAD2* overexpression was associated with prognosis and progression in colorectal cancer ([@b24-ol-0-0-9871]); *ATAD2* overexpression in gastric cancer served as a poor prognostic biomarker ([@b25-ol-0-0-9871]). Thus, studies have revealed that *ATAD2* manifests oncogenic functions in various malignancies. However, the significance of *ATAD2* in RCC remains uncertain.

Materials and methods
=====================

### RCC clinical tissue specimens

Fifty-two pairs of RCC tissue specimens and matched non-cancerous tissues were collected from RCC patients who underwent radical nephrectomy in Beijing Ditan Hospital Capital Medical University (Beijing, China) between September 2015 and June 2017. None of the patients had received chemotherapy or radiotherapy prior to the surgery. All the tissues were immediately frozen in liquid nitrogen after resection and stored at −80°C for further assays.

Written consent was obtained from the RCC patients involved in the current study. The study was approved by the Ethics Committees of Beijing Ditan Hospital Capital Medical University.

### Cell lines and cell culture

Five human RCC cell lines (Caki-1, 786-O, A498, ACHN and Caki-2) and the immortalized normal human renal proximal tubule epithelial cell line HK-2 were obtained from the American Type Culture Collection (Manassas, VA, USA). All the RCC cells were maintained in RPMI-1640 medium (Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA) while HK-2 was cultured in keratinocyte serum-free medium (Gibco; Thermo Fisher Scientific, Inc.). Both culture media contained 10% FBS (Gibco; Thermo Fisher Scientific, Inc.), 100 U/ml penicillin and 100 µg/ml streptomycin (Corning Incorporated, Corning, NY, USA). All the cells were kept in a humidified incubator containing 5% CO~2~ at 37°C.

### Cell transfection

The miR-372 mimics, inhibitors, *ATAD2* overexpression plasmids and *ATAD2* siRNA were produced by GenePharmaCo. (Shanghai, China) and transfected into RCC cells using Lipofectamine^®^ 2000 (Invitrogen; Thermo Fisher Scientific, Inc.) in line with the manufacturer\'s protocol. The cells were harvested 48 h post-transfection for further assays.

### RT-qPCR

TRIzol (Invitrogen; Thermo Fisher Scientific, Inc.) was applied to isolate the total RNAs from RCC tissues and cultured cells following the manufacturers\' protocol. Reverse transcription for cDNA was performed using the TaqMan MicroRNA Reverse Transcription kit (Applied Biosystems; Thermo Fisher Scientific, Inc.). Then, cDNA was amplified using a SYBR-Green mix kit and the ABI 7900 Real-Time PCR system (Applied Biosystems). Primer sequences are shown in [Table I](#tI-ol-0-0-9871){ref-type="table"}. GAPDH was used as endogenous controls for *ATAD2* and EMT-related genes. U6 served as the internal control for miR-372. The relative expression levels were determined using the 2^−∆∆Cq^ method ([@b26-ol-0-0-9871]). RT-qPCR was performed with the following thermocycling conditions: Initial denaturation at 95°C for 10 min, followed by 40 cycles of 95°C for 15 sec, annealing at 50°C for 30 sec, and extension at 72°C for 30 sec.

### Transwell assays

Transwell chamber (8.0 µm pore size, Corning Incorporated) was applied to determine the RCC cell invasion and migration abilities with or without the Matrigel (Corning Incorporated) being precoated. For invasion assay, 1×10^4^ RCC cells in serum-free RPMI-1640 medium were placed into top chambers of the inserts which had been precoated with Matrigel. Then, culture medium containing 10% FBS, as a chemoattractant, was added into bottom chambers. After incubation at 37°C for 48 h in a 5% CO~2~ atmosphere, the cells that remained on the top side of the inserts were removed using a cotton swab while the cells that invaded the bottom side were fixed with 0.1% paraformaldehyde for 15 min and stained with 0.1% crystal violet for 15 min at room temperature. Then, the stained cells were counted under a microscope (IX53; Olympus Corporation, Tokyo, Japan) from five randomly selected visual fields. The difference between the migration and invasion assays was that the insert was not plated with Matrigel for the migration assays.

### Western blotting

Cultured cells were harvested and lysed with RIPA buffer (Beyotime, Shanghai, China) containing the protease inhibitors (Roche, Basel, Switzerland) on ice for 15 min. The BCA method (BCA protein assay kit; Beyotime) was used to determine the concentration of the proteins. Proteins (40 µg) were then separated by 10% SDS-PAGE and transferred onto PVDF membranes (Millipore, Bedford, MA, USA). The membranes were blocked with 5% non-fat milk in TBST at room temperature for 2 h, followed by incubation overnight at 4°C with appropriate primary antibodies which were as follows: antibodies against ATAD2 (1:1000, ab118664, Abcam, Cambridge, MA, USA), Vimentin (1:1000, ab92547, Abcam), E-cadherin (1:1000, ab15148, Abcam) and GAPDH (1:1000, ab9485, Abcam). After incubation with the corresponding horseradish peroxidase-conjugated secondary antibodies (1:2000, ab6721, Abcam) for 2 h at room temperature, the protein bands were visualized using a chemiluminescent imaging system (Pierce, Rockford, IL, USA). Densitometry analysis of the protein blots was conducted using Image-Pro Plus 6.0 software (Media Cybernetics, Inc., Rockville, MD, USA). GAPDH was used as an internal control.

### Luciferase reporter assays

The wild-type (WT) or mutant (MUT) *ATAD2*−3′UTR which contained the miR-372 binding sites was inserted into the luciferase genes in the pGL3 vectors (Promega, Madison, WI, USA). RCC cells were co-transfected with pGL3-WT *ATAD2*−3′-UTR or pGL3-MUT *ATAD2*−3′-UTR and miR-372 mimics. The luciferase activities were detected with the dual-luciferase reporter assay kit (Promega) 48 h after the transfections.

### Statistical analysis

Statistical analyses were performed using SPSS software version 17.0 (SPSS Inc., Chicago, IL, USA). Student\'s t-test, ANOVA and Scheffe post-hoc analysis were applied, where appropriate. A paired Student\'s t-test was performed to analyze the paired data. For analysis on clinical correlation between miR-372 expression and RCC patients\' clinicopathological features, Pearson\'s Chi-square test was used. Spearman\'s correlation method was applied to estimate the correlations between mRNA and miRNA. Kaplan-Meier method was applied to determine the survival rates, and the log-rank test was performed to compare the difference between the survival curves. P\<0.05 was considered to be statistically significant difference.

Results
=======

### Aberrant expression levels of miR-372 and ATAD2 in RCC

To validate whether miR-372 functionally modulates *ATAD2* expression levels in RCC, firstly, we measured miR-372 and *ATAD2* expression levels in RCC tissue samples. Results revealed that RCC tissues presented a lower miR-372 expression level in comparison with the non-tumor tissues ([Fig. 1A](#f1-ol-0-0-9871){ref-type="fig"}), whereas, the expression levels of *ATAD2* in RCC tissues were prominently upregulated when compared to the paired adjacent normal tissues ([Fig. 1B](#f1-ol-0-0-9871){ref-type="fig"}). Similarly, significantly decreased miR-372 expression levels were detected in RCC cells as compared to the normal renal cell HK-2 ([Fig. 1C](#f1-ol-0-0-9871){ref-type="fig"}). We further evaluated *ATAD2* expression levels in RCC cells. As shown in [Fig. 1D](#f1-ol-0-0-9871){ref-type="fig"}, *ATAD2* expression levels were found to be markedly increased in RCC cells compared to HK-2. Additionally, the correlation between miR-372 and *ATAD2* expression levels in RCC tissues was analyzed. The finding of Spearman\'s correlation rank test demonstrated a negative correlation between miR-372 and *ATAD2* expression levels ([Fig. 1E](#f1-ol-0-0-9871){ref-type="fig"}).

### miR-372 suppresses RCC cell migration and invasion

To investigate the functional roles of miR-372 in RCC progression, we performed miR-372 inhibited or overexpressed assays in Caki-1 and 786-O cells, which had the relatively highest or lowest endogenous miR-372 expression levels, by transfecting the miR-372 mimics or inhibitor into 786-O or Caki-1 cells. Successful overexpression or knockdown of miR-372 in 786-O or Caki-1 cells was confirmed using RT-qPCR ([Fig. 2A and 2C](#f2-ol-0-0-9871){ref-type="fig"}). Then, Transwell assays were conducted to confirm the functions of miR-372 in RCC cell migration and invasion. The findings showed that miR-372 overexpression significantly reduced 786-O cell migration and invasion ([Fig. 2B](#f2-ol-0-0-9871){ref-type="fig"}). By contrast, there was a significant increase in cell invasion and migration of Caki-1 treated with miR-372 inhibitor ([Fig. 2D](#f2-ol-0-0-9871){ref-type="fig"}).

### miR-372 suppresses RCC cell EMT

Next, we monitored alterations of EMT markers, including Vimentin and E-Cadherin, to investigate the functions of miR-372 in EMT of RCC cells. As expected, results of RT-qPCR and western blot analysis both demonstrated that E-Cadherin expression levels were obviously increased, whereas the Vimentin expression levels were markedly reduced in miR-372 overexpressed 786-O cells ([Fig. 3A and B](#f3-ol-0-0-9871){ref-type="fig"}). By contrast, Vimentin was upregulated in miR-372-suppressed Caki-1 cells, while E-Cadherin was prominently downregulated ([Fig. 3C and D](#f3-ol-0-0-9871){ref-type="fig"}). Our data revealed that miR-372 overexpression could suppress the RCC cell EMT progression.

### ATAD2 is a direct target of miR-372 in RCC cell lines

The significant impact of miR-372 on the metastasis of RCC cells prompted us to investigate the mechanisms underlying its functional effects. The data from Targetscan database revealed that *ATAD2* had complementary binding sites for miR-372 ([Fig. 4A](#f4-ol-0-0-9871){ref-type="fig"}). Then, dual-luciferase reporter assays were performed to validate the association between *ATAD2* and miR-372. The results showed that miR-372 significantly reduced the luciferase activities of *ATAD2*−3′UTR-WT without having obvious effects on that of *ATAD2*−3′UTR-Mut ([Fig. 4B](#f4-ol-0-0-9871){ref-type="fig"}). We also investigated whether miR-372 could regulate the *ATAD2* expression levels in RCC cells. The results of RT-qPCR indicated that miR-372 overexpression significantly reduced *ATAD2* expression levels in 786-O cells ([Fig. 4C](#f4-ol-0-0-9871){ref-type="fig"}) while inhibition of miR-372 significantly elevated ATAD2 expression levels in Caki-1 cells ([Fig. 4D](#f4-ol-0-0-9871){ref-type="fig"}).

### ATAD2 mediated the biological functions of miR-372 in RCC cell invasion and migration

Next, we performed rescue experiments to verify that miR-372 inhibited RCC metastasis ability by directly reducing *ATAD2*. First, we obtained miR-372 overexpressed 786-O cells or miR-372 suppressed Caki-1 cells by transfecting miR-372 mimics or inhibitor. Then, to verify that the biological functions of miR-372 in RCC was modulated by *ATAD2*, we transfected ATAD2 overexpressing vector or *ATAD2* siRNA into miR-372 overexpressed 786-O cells or miR-372 suppressed Caki-1 cells, inducing an increase or decrease of *ATAD2* expression ([Fig. 5A and B](#f5-ol-0-0-9871){ref-type="fig"}). Next, Transwell assays were performed to determine the migration and invasion capacities. Findings demonstrated that *ATAD2* upregulation markedly enhanced the invasion and migration abilities of miR-372 overexpressed 786-O cells ([Fig. 5C](#f5-ol-0-0-9871){ref-type="fig"}). On the contrary, knockdown of *ATAD2* dramatically reduced the invasion and migration abilities of miR-372 suppressed Caki-1 cells ([Fig. 5D](#f5-ol-0-0-9871){ref-type="fig"}). miR-372 inhibited RCC cell EMT by regulating *ATAD2*. We further investigated the functions of *ATAD2* in mediating the functional roles of miR-372 in RCC EMT progress by qRT-PCR and western blots. As expected, in miR-372 overexpressed 786-O cells, E-cadherin expression levels were significantly reduced and vimentin expression levels were prominently enhanced by *ATAD2* overexpression ([Fig. 6A and 6B](#f6-ol-0-0-9871){ref-type="fig"}). However, *ATAD2* silence significantly elevated the E-cadherin expression levels and decreased the vimentin expression levels in miR-372 suppressed Caki-1 cells ([Fig. 6C and D](#f6-ol-0-0-9871){ref-type="fig"}). The data indicated that miR-372 suppressed RCC cell EMT process by regulation of *ATAD2*.

### Aberrant expression levels of miR-372 and ATAD2 were correlated with clinicopathological features and prognosis of RCC patients

As we had confirmed the functional effects of miR-372 and *ATAD2* in RCC, subsequently, we further investigated the clinical significance of miR-372 and *ATAD2* in RCC. The RCC patients involved in current study were divided into two groups based on the mean expression level of miR-372. Kaplan-Meier abalysis demonstrated that RCC patients with relatively low miR-372 expression levels had significantly decreased OS ([Fig. 7A](#f7-ol-0-0-9871){ref-type="fig"}, P=0.0312) and DFS ([Fig. 7B](#f7-ol-0-0-9871){ref-type="fig"}, P=0.0366). In addition, *ATAD2* high-expressing RCC patients presented shorter OS and DFS compared to *ATAD2* low-expressing cases ([Fig. 7C and D](#f7-ol-0-0-9871){ref-type="fig"}). Correlation between miR-372 expression and clinical features analysis implied that miR-372 expression levels were relevant to lymph node metastasis, TNM stage and tumor differentiation (P=0.0015, 0.0075 and 0.0103, respectively, [Table II](#tII-ol-0-0-9871){ref-type="table"}).

Discussion
==========

RCC is the most common neoplasm of the adult kidney, and the morbidity and mortality rates are increasing at a rate of 2--3% per decade ([@b27-ol-0-0-9871]). However, the curative effects of radiotherapy and traditional chemotherapy in advanced RCC therapy are limited ([@b28-ol-0-0-9871]). Additionally, although surgery is often curative for localized disease, majority of these patients experience metastasis or relapses, which is associated with poor prognosis. Therefore, it is of crucial significance to understand the mechanisms underlying RCC metastasis and recurrence to explore novel anti-RCC therapeutic targets. Previous studies revealed that miRNAs may provide new directions for earlier diagnosis as well as better prognosis of RCC ([@b29-ol-0-0-9871]).

Recent studies have proposed the antitumor effects of miR-372 in various malignancies. Aberrant miR-372 expression has been identified as novel prognostic as well as diagnostic marker for osteosarcoma ([@b30-ol-0-0-9871]) and colorectal cancer ([@b31-ol-0-0-9871]). Additionally, studies by Wu *et al* indicated that declined miR-372 expression in hepatocellular carcinoma was relevant to tumor metastasis and poor prognosis ([@b32-ol-0-0-9871]); Kong *et al* reported that miR-372 repressed prostate cancer cell invasion and migration via regulating *p65* ([@b33-ol-0-0-9871]); Liu *et al* found that miR-372 inhibited the progression of endometrial carcinoma via the regulation of *RhoC* ([@b34-ol-0-0-9871]). Consistent with these findings, we found that miR-372 was obviously downregulated in RCC and its decreased expression levels were related to poor prognosis and worse clinicopathological parameters of RCC patients. Furthermore, miR-372 overexpression suppressed RCC cell EMT and metastasis. The data suggested that miR-372 played an inhibitory role in RCC metastasis and progression.

Previous studies have identified and validated an array of possible direct targets of miR-372, such as *TXNIP, ULK1* and *CDK2* ([@b35-ol-0-0-9871]--[@b37-ol-0-0-9871]), suggesting that miR-372 is an antitumor miRNA which plays a pivotal role in the initiation and progression of cancer. To extend that observation, we assessed the relationship between miR-372 and *ATAD2* in RCC. *ATAD2* has been identified as a novel candidate oncogene and possibly a therapeutic target for several types of human cancers ([@b38-ol-0-0-9871]). For instance, Hwang *et al* found that *ATAD2* functioned as a poor prognostic biomarker in hepatocellular carcinoma ([@b39-ol-0-0-9871]); Wan *et al* reported that *ATAD2* overexpression in ovarian carcinoma indicated poor prognosis ([@b40-ol-0-0-9871]); Shang *et al* reported that overexpression of *ATAD2/ANCCA* in endometrial carcinoma was related to poor prognosis and tumor progression ([@b41-ol-0-0-9871]). These studies suggested that *ATAD2* might have a potential as a therapeutic target for malignancies. Although the correlation between clinicopathological features and *ATAD2* expression levels has been studied in multiple tumors, little is known about *ATAD2* in RCC. Herein, the ectopic upregulation of *ATAD2* in RCC was presented, which demonstrated a poor prognosis of RCC patients. Moreover, *ATAD2* was identified as a direct target of miR-372 in RCC cells. Importantly, the inhibitory functions of miR-372 in RCC cell metastasis and EMT were confirmed to be regulated by *ATAD2*.

In conclusion, the findings in current research demonstrated a significant decrease of miR-372 expression levels and a notable increase of *ATAD2* expression levels in RCC. Additionally, miR-372 overexpression had similar effects on repressing RCC cell invasion, migration and EMT as *ATAD2* silence. Moreover, *ATAD2* was confirmed to be a direct target of miR-372 and the antitumor effects of miR-372 on RCC progression were partially mediated by *ATAD2*. The findings suggested that miR-372/*ATAD2* axis may be attractive biomarkers and therapeutic targets for RCC patients.
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![miR-372 is downregulated and *ATAD2* is upregulated in RCC. (A) miR-372 expression levels in normal and RCC tissues. (B) *ATAD2* expression levels in RCC tissues and adjacent normal tissues were detected by RT-qPCR. (C) miR-372 expression levels in RCC and normal renal cells. (D) *ATAD2* expression levels in RCC and normal renal cells. (E) Spearman\'s correlation analysis between the miR-372 and *ATAD2* expression levels in RCC tissues. \*P\<0.05, \*\*P\<0.01, \*\*\*P\<0.001.](ol-17-02-2400-g00){#f1-ol-0-0-9871}

![miR-372 suppresses cell invasion and migration in RCC cells. (A) miR-372 expression levels in 786-O cells with transfection of miR-372 mimics. (B) Cell invasion and migration were measured by Transwell assays in 786-O treated with miR-372 mimics. (C) miR-372 expression levels in Caki-1 cells with transfection of miR-372 inhibitor. (D) Cell invasion and migration were measured by Transwell assays in Caki-1 cells with transfection of miR-372 inhibitor. \*P\<0.05, \*\*P\<0.01.](ol-17-02-2400-g01){#f2-ol-0-0-9871}

![miR-372 suppressed EMT in RCC cells. (A and B) miR-372 overexpression in 786-O cells elevated the E-cadherin expression levels and reduced the Vimentin expression levels. (C and D) Inhibition of miR-372 in Caki-1 cells downregulated the E-cadherin expression levels and enhanced the Vimentin expression levels. \*P\<0.05, \*\*P\<0.01.](ol-17-02-2400-g02){#f3-ol-0-0-9871}

![*ATAD2* is the direct target of miR-372 in RCC. (A) The putative binding sites of miR-372 in the *ATAD2* 3′-UTR. (B) The luciferase activities of the *ATAD2* 3′UTR was detected by luciferase reporter gene assays in RCC cells which were cotransfected with wild-type *ATAD2* 3′UTR or mutational type *ATAD2* 3′UTR and miR-372 mimics, respectively. (C) *ATAD2* expression in 786-O treated with miR-372 mimics. (D) *ATAD2* expression in Caki-1 treated with miR-372 inhibitor. \*P\<0.05.](ol-17-02-2400-g03){#f4-ol-0-0-9871}

![Altering expression of *ATAD2* partly reverses miR-372-mediated functions in RCC cell invasion and migration. (A and B) *ATAD2* expression levels in miR-372-overexpressed 786-O cells and miR-372-suppressed Caki-1 cells, which were cotransfected with *ATAD2* overexpression plasmid or *ATAD2* siRNA respectively. (C and D) Transwell assays were conducted to determine cell invasion and migration abilities of (C) miR-372-overexpressed 786-O cells and (D) miR-372-suppressed Caki-1 cells, which were cotransfected with *ATAD2* overexpression plasmid or *ATAD2* siRNA respectively. \*P\<0.05, \*\*P\<0.01.](ol-17-02-2400-g04){#f5-ol-0-0-9871}

![Altering of *ATAD2* expression levels reversed the effect of miR-372 on RCC cell EMT process. (A and B) Overexpression of *ATAD2* in miR-372-overexpressed 786-O cells decreased the E-cadherin expression levels and increased the Vimentin expression levels. (C and D) Knockdown of *ATAD2* in miR-372-suppressed Caki-1 cells upregulated E-cadherin and downregulated Vimentin significantly. \*P\<0.05, \*\*P\<0.01.](ol-17-02-2400-g05){#f6-ol-0-0-9871}

![Prognostic value of miR-372 and *ATAD2* in RCC patients. (A) OS and (B) DFS of RCC patients with high and low miR-372 expression levels. (C) OS and (D) DFS of RCC patients with high and low *ATAD2* expression levels.](ol-17-02-2400-g06){#f7-ol-0-0-9871}

###### 

Primer sequences for RT-qPCR.

  Primer       Sequence
  ------------ ---------------------------------
  miR-372      F: 5′-AGCCTAAAGTGCTGCGACATT-3′
               R: 5′-GTGCAGGGTCCGAGGT-3′
  U6           F: 5′-CTCGCTTCGGCAGCACA-3′
               R: 5′-AACGCTTCACGAATTTGCGT-3′
  ATAD2        F: 5′-GGAATCCCAAACCACTGGACA-3′
               R: 5′-GGTAGCGTCGTCGTAAAGCACA-3′
  GAPDH        F: 5′-GAAGGTGAAGGTCGGAG-3′
               R: 5′-GAAGATGGTGATGGGAT-3′
  E-cadherin   F: 5′-CACCTGGAGAGAGGCCATGT-3′
               R: 5′-TGGGAAACATGAGCAGCTCT-3′
  Vimentin     F: 5′-AGCTGCAGGCTCAGATTCAGGA-3′
               R: 5′-CGGTTGGCAGCCTCAGAGAGGT-3′

F, forward; R, reverse; U6, small nuclear RNA, snRNA; ATAD2, ATPase family AAA domain-containing protein 2; GAPDH, glyceraldehyde-3-phosphate dehydrogenase.

###### 

Correlation of miR-372 expression with the clinicopathological characteristics of the RCC patients.

                               miR-372^[a](#tfn3-ol-0-0-9871){ref-type="table-fn"}^ expression                                                               
  ----------------------- ---- ----------------------------------------------------------------- ----- ----------------------------------------------------- --------
  Age (years)                                                                                          0.2016                                                0.3718
    \>60                  27   11                                                                16                                                          
    ≤60                   25   10                                                                15                                                          
  Sex                                                                                                  0.3124                                                0.0132
    Male                  26     9                                                               17                                                          
    Female                26   12                                                                14                                                          
  Tumor size (cm)                                                                                      0.0614                                                2.1431
    ≥5.0                  24     6                                                               18                                                          
    \<5.0                 28   15                                                                13                                                          
  TNM stage                                                                                            0.0075^[b](#tfn4-ol-0-0-9871){ref-type="table-fn"}^   7.3920
    I--II                 26   17                                                                  9                                                         
    III                   26     4                                                               22                                                          
  Histological type                                                                                    0.0765                                                1.0125
    Clear cell            28   12                                                                16                                                          
    Papillary             24     9                                                               15                                                          
  Tumor differentiation                                                                                0.0103^[b](#tfn4-ol-0-0-9871){ref-type="table-fn"}^   3.7846
    Well and Moderate     25   16                                                                  9                                                         
    Poor                  27     5                                                               22                                                          
  Lymph node metastasis                                                                                0.0015^[b](#tfn4-ol-0-0-9871){ref-type="table-fn"}^   9.5623
    Present               26     4                                                               22                                                          
    Absent                26   17                                                                  9                                                         

TNM, tumor-node-metastasis

The mean expression level of miR-372 was used as the cut off

Statistically significant.

[^1]: Contributed equally
